Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET

Company Participants

John Shannon - Chief Executive Officer
Steve Pieper - Chief Financial Officer
Allison Wey - Senior Vice President of Investor Relations, Corporate Communications

Conference Call Participants

Chase Knickerbocker - Craig-Hallam
Leland Gershell - Oppenheimer.
Oren Livnat - HC Wainwright
Nik Gasic - Leerink Partners
David Amsellem - Piper Sandler

Operator

Hello and welcome to the Xeris Biopharma Third Quarter 2024 Financial Results Conference Call. My name is Harry and I'll be your operator today. All lines are currently in listen-only mode and there'll be an opportunity for Q&A after management's prepared remarks. [Operator Instructions].

I would now like to hand the conference over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications. Thank you, please go ahead.

Allison Wey

Thank you, Harry, and good morning. We appreciate you joining our third quarter results call today. I'm joined by John Shannon, our CEO; and Steve Pieper, our CFO. This morning we issued a press release with our detailed results which can be found on our website. After our prepared remarks, we will open the line for questions.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, prospects and financial performance.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. For more information on such risks, please refer to our Earnings Release and Risk Factors included in our SEC filing.

Any forward-looking statements in this call represent our views only as the date of this call and subject to applicable law. We disclaim any obligations to update such statements.

Let me now pass the call over to John.

John Shannon

Thanks Alison and good morning everyone. I'm excited and proud to report another record-breaking quarter with total revenue of over $54 million and product revenue of nearly $53 million, led by strong demand of Recorlev and Gvoke. Our product revenue growth of 27% marks the 12th consecutive quarter of over 20% growth. That's right, 12 quarters in a row of over 20% growth, with the last two quarters accelerating to 26% and now 27% respectively.

The entire Xeris team is focused on driving growth, and I'm so proud to see them executing on all fronts. In addition to our outstanding commercial success, we also significantly advanced our lead pipeline product, XP8121, our once-weekly Subcu Levothyroxine, and executed as planned on all of our technology partner programs.